Roberta Esposito

The paper identifies cell type-specific lncRNAs in CRC using single-cell and bulk transcriptomes, showing their enrichment in epithelial cells and validating their role in CRC proliferation.

The paper introduces TransCistor, a framework to identify cis-regulatory lncRNAs with controlled false discovery rates, finding that only a minority of lncRNAs are cis-acting, primarily as activators.

The paper identifies mutated long noncoding RNAs (lncRNAs) as contributors to tumour cell fitness through experimental validation of their oncogenic effects.

The paper identifies 60 high-confidence oncogenic lncRNAs in NSCLC using CRISPR deletion screens and ASO validation, revealing therapeutic vulnerabilities.

This paper shows that temporarily inhibiting DNA-PK increases CRISPR-Cas9 deletion efficiency by delaying NHEJ, improving experimental outcomes across multiple cell lines and guide RNAs.